Treatment of secondary pulmonary hypertension with bosentan and its pharmacokinetic monitoring in ESRD

Bosentan Therapy for Pulmonary Arterial Hypertension

Lewis J. Rubin, David B. Badesch, Robyn J. Barst et al. · New England Journal of Medicine · 2002 · 2.7K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study

Richard N. Channick, G Simonneau, Olivier Sitbon et al. · The Lancet · 2001 · 1.5K citations

Medicine, Pharmacology, Pharmacotherapy +13

Increased Plasma Endothelin-1 in Pulmonary Hypertension: Marker or Mediator of Disease?

Robert D. Levy, Peter Černáček, David Langleben · Annals of Internal Medicine · 1991 · 978 citations

Medicine, Cardiology, Physiology +11

Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension

Ronald J. Raymond, Alan L. Hinderliter, Park W. Willis et al. · Journal of the American College of Cardiology · 2002 · 823 citations

Medicine, Clinical Sciences, Internal Medicine +16

Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure.

Robert Cody, Garrie J. Haas, Philip F. Binkley et al. · Circulation · 1992 · 646 citations

Medicine, Cardiology, Physiology +14